Dizal Pharmaceutical Co (SHSE:688192) Beta: 0.8821 (As of Jun. 27, 2026)


SHSE:688192 Dizal Pharmaceutical Co Ltd SHSE:688192
36 GF Score
Price ¥36.49
GF Value ¥132.14
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Dizal Pharmaceutical Co Beta?

Dizal Pharmaceutical Co SHSE:688192 -6.56% 36 Beta is 0.8821 as of Jun. 27, 2026. GuruFocus rates SHSE:688192 with a GF Score™ of 36/100 and a GF Value™ of ¥132.14 (Possible Value Trap). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Dizal Pharmaceutical Co's Beta is 0.8821.


Dizal Pharmaceutical Co  (SHSE:688192) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Dizal Pharmaceutical Co Beta Related Terms


Dizal Pharmaceutical Co Beta Historical Data

* Premium members only.

The historical data trend for Dizal Pharmaceutical Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dizal Pharmaceutical Co Beta Chart

Dizal Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 1.22 1.34

Dizal Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 0.82 0.94 1.34 1.01

SHSE:688192 vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dizal Pharmaceutical Co Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's Beta distribution charts can be found below:

* The bar in red indicates where Dizal Pharmaceutical Co's Beta falls into.


SHSE:688192
36GF Score
Dizal Pharmaceutical Co Ltd SHSE:688192
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dizal Pharmaceutical Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.8821 mean?
Dizal Pharmaceutical Co (SHSE:688192) has a Beta of 0.8821 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Dizal Pharmaceutical Co and its competitors.
Is Dizal Pharmaceutical Co's Beta too high?
Dizal Pharmaceutical Co's current Beta is 0.8821. Overall, Dizal Pharmaceutical Co has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's Beta compare to ZTS?
Dizal Pharmaceutical Co's Beta of 0.8821 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Dizal Pharmaceutical Co and its competitors. Dizal Pharmaceutical Co's current Beta is 0.8821. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥132.14, compared to a current price of ¥36.49 — trading 72.4% below its estimated fair value. The current Beta is 0.8821. Dizal Pharmaceutical Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current Beta is 0.8821 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?

Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥36.49 is trading 72.4% below its estimated GF Value™ of ¥132.14. GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:688192:

  • Beta: 0.8821
  • GF Value™: ¥132.14 vs. price of ¥36.49 (72.4% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dizal Pharmaceutical Co Business Description

Address Jinghui East Road, Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District, Jiangsu Province, Wuxi City, CHN, 201203
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
36GF Score

Get the complete analysis for SHSE:688192

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.49
Price
¥132.14
GF Value